Acne Vulgaris Treatment Market Growth Boosted By Leading Players Allergan plc, GlaxoSmithKline plc, Valeant Pharmaceutical International Inc., F.Hoffmann-La Roche AG, Mylan, N.V., Bayer AG, Janssen Pharma Inc., Galderma Inc., Pfizer Inc

According to a study published in the British Journal of Dermatology in 2015, 9.4% of global population was estimated to be affected by acne. Moreover, globally, acne is the eight most prevalent disease. The U.S. is the largest market for acne vulgaris treatment products. According to study by National Institute of Health (NIH), in 2013, over US$ 3 Billion was spent for treating acne vulgaris in the U.S. In 2014, according to American Academy of Dermatology, the number of acne vulgaris patient aged 25 years and above, especially women, is rising significantly. Furthermore, low awareness regarding the factors causing acne is another factor leading to increasing prevalence acne vulgaris.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1260

Treatment for acne on an average lasts for two years, therefore companies capitalize on this and earn sustainable revenue from acne treatment products. Majority of the population suffering from acne prefer OTC products as first line therapy. However, some have to visit dermatologist to cure acne vulgaris on account of ineffective result from OTC products.

New treatments such as cosmetic (laser, chemical peel, and photodynamic therapy) and surgical procedures are been developed for treatment of scarring. Increasing consumer inclination towards alternative way to treat acne vulgaris such as herbal therapy (tee tree oil), owing to low side effects is another factor expected to aid in growth of the acne vulgaris treatment market. Home-based devices for acne removal such as revive light therapy and neutrogena light therapy are gaining significant traction over the forecast period.

Key players in the acne vulgaris treatment market are focusing on collaboration, acquisition, and new product development strategies in order to enhance their product offerings and sustaining their position in the market. For instance, in 2017, L’Oréal — a global beauty company — signed an agreement with Valeant Pharmaceuticals International, Inc. to acquire its skin care brands portfolio which includes anti-acne brand AcneFree at US$1.3 billion. Also, in November 2017 Novan Inc., announced its plans to conduct phase three clinical trial for its new anti-acne molecule. Novan has unique nitric oxide technology, Nitrici, through which a timed release of nitric oxide from chemical entity is possible.

This is beneficial as nitric oxide has natural ability to revitalize tissue, kill invading microorganisms, prevent clotting, regulate inflammation, and even aid in removing cancer cells. Moreover, in 2017, Valeant Pharmaceuticals International, Inc. signed an agreement with Haitong International Zhonghua Finance Acquisition Fund I, L.P, to sell its Obagi Medical Products business for US$ 190 million in cash. Obagi Medical Products have high presence in acne treatment products market.

Key players in the global acne vulgaris treatment market are Allergan plc, GlaxoSmithKline plc, Valeant Pharmaceutical International Inc., F.Hoffmann-La Roche AG, Mylan, N.V., Bayer AG, Janssen Pharma Inc., Galderma Inc., Pfizer Inc., and Novan Inc.

Get Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1260

Acne Vulgaris Treatment Market Taxonomy:

On the basis of product type, the global acne vulgaris treatment market is segmented into:

Medications
Benzoyl peroxides
Retinoids
Systemic and topical Antibiotics
Hormonal Agents
Others (Salicylic Acid, Azelic, Dapsone, and Alternative therapy)
Devices
Laser devices
Heat extraction devices
Others

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.